a Haloproginis a topical antifungal agent. Its structuredoes not contain any of the functional groups typically exploited in hydrogen bond based co-crystal design. On the other hand, its 1-iodoalkyne moiety is nicely tailored to a crystal engineering strategy based on halogen bonding. Here we describe the formation of threepolymorphs of haloprogin and of threecocrystalsthat this active pharmaceutical ingredient forms with both neutral and ionic co-crystal formers. The halogen bond plays a major role in all of the six structures and the interaction is thus confirmed to be a valuable tool which may complement the hydrogen bond when polymorph and co-crystal screeningsare pursued.
IntroductionPolymorph and co-crystal screeningsareuseful strategies to find new solid forms of active pharmaceutical ingredients(APIs),in order to alter/improve their physical properties without changing their chemical identities or biological activities. 1 Most commonly APIs have hydrogen bonding donor and acceptor groups that are involved in the binding of the co-crystal former (CCF), e.g., carboxylic acids and aromatic nitrogen atoms havebeen proven particularly reliable moieties in hydrogen bonding (HB) driven formation of API-CCF adducts. 2 On the other hand, the design of pharmaceutical co-crystals involving APIs devoid of strong hydrogen bonddonor sitesisquite challenging.Halogen atoms are frequently present in drugs molecules and we considered that they can be used to drive the formation of pharmaceutical co-crystals if the halogen bonding 3 (XB) is used. Recently we demonstrated that the iodoalkyne moiety of an API can be successfully used to prepare halogen-bonded cocrystalswith improved physicochemical properties. 4 In this paper we describe a further case where the same moiety drives the formation of co-crystals with neutral and anionic partners. More important, we describe how the iodoalkyne moiety can play an active role in the formation of different polymorphs of an API.Haloprogin1(1,2,4-trichloro-5-[(3-iodoprop-2-yn-1-yl)oxy]benzene) is the API of antimycotic topical drugswith brand names of Halotex®, Mycanden®, Mycilan® and Polik® (Scheme 1).
5No structures involving 1are reported in the Cambridge Structural Database (CSD), 6 consistent with the fact that it may represent a difficult challenge if a standard approach for polymorph and co-crystal formation is pursued since it does notcontain any of the functional groupstypically required for a HB-based strategy. On the other hand, an iodine atom bound to the sphybridisedcarbon atom displays a particularly anisotropic distribution of its electron density.7 A region of remarkably positive electrostatic potential, the so-called positive -hole, 8 is present on the outermost surface of the iodine atom and along the extension of the C-I covalent bond.This specific feature makes the iodoalkynemoiety a very good XB donorsite. 9,10 We reasoned that the presence in 1of one efficient XBdonor sitealong with the absence of strong HBdonor sites represents a unique opportunity to explore t...